Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Van Hasselt

Showing results (21-30 of 90) with videos related to

Pageof 9
Sort By:
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|May 29, 2023
Does nonlinear blood-brain barrier transport matter for (lower) morphine dosing strategies?Berfin Gülave, Divakar Budda, M A A Saleh, et al.
Scientific Reports|March 23, 2022
Publisher Correction: Anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistanceAnyue Yin, Johan G C van Hasselt, Henk-Jan Guchelaar, et al.
Scientific Reports|March 11, 2022
Anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistanceAnyue Yin, Johan G C van Hasselt, Henk-Jan Guchelaar, et al.
Clinical Pharmacology and Therapeutics|June 3, 2011
Population pharmacokinetic-pharmacodynamic analysis of trastuzumab-associated cardiotoxicityJ G C van Hasselt, A H Boekhout, J H Beijnen, et al.
Frontiers in Physiology|September 28, 2017
Mechanistic Systems Modeling to Improve Understanding and Prediction of Cardiotoxicity Caused by Targeted Cancer TherapeuticsJaehee V Shim, Bryan Chun, Johan G C van Hasselt, et al.
CPT: Pharmacometrics & Systems Pharmacology|August 28, 2015
Integrated Simulation Framework for Toxicity, Dose Intensity, Disease Progression, and Cost Effectiveness for Castration-Resistant Prostate Cancer Treatment With EribulinJ G C van Hasselt, A Gupta, Z Hussein, et al.
CPT: Pharmacometrics & Systems Pharmacology|August 28, 2015
Disease Progression/Clinical Outcome Model for Castration-Resistant Prostate Cancer in Patients Treated With EribulinJ G C van Hasselt, A Gupta, Z Hussein, et al.
Antimicrobial Agents and Chemotherapy|April 14, 2010
Population pharmacokinetics of vancomycin in premature Malaysian neonates: identification of predictors for dosing determinationYoke-Lin Lo, Johan G C van Hasselt, Siow-Chin Heng, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|May 29, 2026
Towards Precision Piperacillin Dosing in the Critically IllDirk J A R Moes, Martine G Caris, Anne G Märtson, et al.
British Journal of Clinical Pharmacology|December 11, 2012
Optimizing drug development of anti-cancer drugs in children using modelling and simulationJohan G C van Hasselt, Natasha K A van Eijkelenburg, Jos H Beijnen, et al.
Pageof 9

Showing results (21-30 of 90) with videos related to

Sort By:
Pageof 9
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|May 29, 2023
Does nonlinear blood-brain barrier transport matter for (lower) morphine dosing strategies?Berfin Gülave, Divakar Budda, M A A Saleh, et al.
Scientific Reports|March 23, 2022
Publisher Correction: Anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistanceAnyue Yin, Johan G C van Hasselt, Henk-Jan Guchelaar, et al.
Scientific Reports|March 11, 2022
Anti-cancer treatment schedule optimization based on tumor dynamics modelling incorporating evolving resistanceAnyue Yin, Johan G C van Hasselt, Henk-Jan Guchelaar, et al.
Clinical Pharmacology and Therapeutics|June 3, 2011
Population pharmacokinetic-pharmacodynamic analysis of trastuzumab-associated cardiotoxicityJ G C van Hasselt, A H Boekhout, J H Beijnen, et al.
Frontiers in Physiology|September 28, 2017
Mechanistic Systems Modeling to Improve Understanding and Prediction of Cardiotoxicity Caused by Targeted Cancer TherapeuticsJaehee V Shim, Bryan Chun, Johan G C van Hasselt, et al.
CPT: Pharmacometrics & Systems Pharmacology|August 28, 2015
Integrated Simulation Framework for Toxicity, Dose Intensity, Disease Progression, and Cost Effectiveness for Castration-Resistant Prostate Cancer Treatment With EribulinJ G C van Hasselt, A Gupta, Z Hussein, et al.
CPT: Pharmacometrics & Systems Pharmacology|August 28, 2015
Disease Progression/Clinical Outcome Model for Castration-Resistant Prostate Cancer in Patients Treated With EribulinJ G C van Hasselt, A Gupta, Z Hussein, et al.
Antimicrobial Agents and Chemotherapy|April 14, 2010
Population pharmacokinetics of vancomycin in premature Malaysian neonates: identification of predictors for dosing determinationYoke-Lin Lo, Johan G C van Hasselt, Siow-Chin Heng, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|May 29, 2026
Towards Precision Piperacillin Dosing in the Critically IllDirk J A R Moes, Martine G Caris, Anne G Märtson, et al.
British Journal of Clinical Pharmacology|December 11, 2012
Optimizing drug development of anti-cancer drugs in children using modelling and simulationJohan G C van Hasselt, Natasha K A van Eijkelenburg, Jos H Beijnen, et al.
Pageof 9